Analysis Tools
mortality/aging
 |
• mean survival time is 90.5 weeks of age
|
neoplasm
|
|
• mice show early formation of prostate tumors before 20 weeks of age
• tumors in 20 week old mice show an initial response to androgen deprivation therapy (by surgical castration), however by 8 weeks post-castration, mice develop castration-resistant prostate cancer in which tumors are insensitive to everolimus, a PI3K/AKT targeted therapy
• castration-resistant prostate tumors however are sensitive to a combination therapy of everolimus and U0126, a MEK1/2 inhibitor, showing increased apoptosis following treatment
|
|
|
• from 20 weeks, all mice develop adenocarcinomas in the lateral, dorsal, and ventral prostate lobes, however tumors in the anterior prostate are rare
|
|
|
• mice gradually develop prostatic intraepithelial neoplasia as early as 8 weeks in the dorsolateral lobes that progress to well-differentiated tumors by 15 weeks
|
|
|
• at 50-60 weeks of age, 10% of mice develop distant spread of tumor metastases primarily in the loco-regional lymph nodes and occasionally in lung and liver
• by 75-90 weeks of age, about 60% of mice show distant spread of tumor metastases
|
reproductive system
|
|
• mice show early formation of prostate tumors before 20 weeks of age
• tumors in 20 week old mice show an initial response to androgen deprivation therapy (by surgical castration), however by 8 weeks post-castration, mice develop castration-resistant prostate cancer in which tumors are insensitive to everolimus, a PI3K/AKT targeted therapy
• castration-resistant prostate tumors however are sensitive to a combination therapy of everolimus and U0126, a MEK1/2 inhibitor, showing increased apoptosis following treatment
|
|
|
• from 20 weeks, all mice develop adenocarcinomas in the lateral, dorsal, and ventral prostate lobes, however tumors in the anterior prostate are rare
|
|
|
• mice gradually develop prostatic intraepithelial neoplasia as early as 8 weeks in the dorsolateral lobes that progress to well-differentiated tumors by 15 weeks
|
endocrine/exocrine glands
|
|
• mice show early formation of prostate tumors before 20 weeks of age
• tumors in 20 week old mice show an initial response to androgen deprivation therapy (by surgical castration), however by 8 weeks post-castration, mice develop castration-resistant prostate cancer in which tumors are insensitive to everolimus, a PI3K/AKT targeted therapy
• castration-resistant prostate tumors however are sensitive to a combination therapy of everolimus and U0126, a MEK1/2 inhibitor, showing increased apoptosis following treatment
|
|
|
• from 20 weeks, all mice develop adenocarcinomas in the lateral, dorsal, and ventral prostate lobes, however tumors in the anterior prostate are rare
|
|
|
• mice gradually develop prostatic intraepithelial neoplasia as early as 8 weeks in the dorsolateral lobes that progress to well-differentiated tumors by 15 weeks
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:214242 | |
